"According to Chinese Medicine News, BioAlliance Pharma, committed to professional and orphans oncology products reported, recently announced the phase Ⅱtrial results of liver cancer drug Livatag in the International Liver Cancer Association (ILCA) Annual Conference

De Lyon, professor of liver disease in public hospice, and the clinical trial principal investigator Pr. Philippe Merle, announced the observed initial survival results of Livatag in unresectable hepatocellular carcinoma (primary liver cancer) patients: in 50 patients, 28 patients were randomized to receive Livatag arterial injection, 1 injection every 4 weeks, totaly three injections; with compared the 15 months’ median survival group, Livatag survival time of treated group significantly increased, reaching 31.7 months (P <0.05); received 3 injections of the patients had a better response to treatment, median survival increased to 33 months (P <0.05). "